eMedicine Specialties > Otolaryngology and Facial Plastic Surgery > Head & Neck Surgery

Malignant Tumors of the Nasal Cavity: Treatment

Author: Ricardo L Carrau, MD, Professor, Department of Otolaryngology-Head and Neck Surgery, Department of Neurological Surgery, Department of Oral and Maxillofacial Surgery, University of Pittsburgh School of Medicine; Professor of Oral and Maxillofacial Surgery, University of Pittsburgh School of Dental Medicine
Coauthor(s): Yew Kwang Ong, MBBCh, Fellow in Craniofacial/Skull Base Surgery, Department of Otolaryngology, University of Pittsburgh Medical Center; C Arturo Solares, MD, Assistant Professor of Otolaryngology, Co-Director, MCG Skull Base Institute, Department of Otolaryngology-Head and Neck Surgery, Medical College of Georgia
Contributor Information and Disclosures

Updated: Jan 25, 2010

Treatment

Medical Therapy

Surgery is the mainstay of treatment for most sinonasal tumors. Radiation as the sole modality of treatment is recommended for unresectable cases, poor surgical candidates, or for lymphoreticular tumors. Combination therapy of surgery and adjuvant radiotherapy with or without chemotherapy is given in situations with an advanced tumor (T3 and T4), positive surgical margins, perineural spread, perivascular invasion, cervical lymphatic metastasis, and in recurrent tumors. Chemotherapy may also have a palliative role for cytoreduction.

Radiation therapy

Radiation may be used as a single modality, as an adjunct to surgery, or as palliative therapy. It is the primary treatment for lymphoreticular tumors and in patients who are poor surgical candidates, refuse surgical treatment, or have tumors that are deemed inoperable. As an adjunct to surgery, it can be given preoperatively or postoperatively with similar oncological results. Preoperative radiation is given in cases of bulky tumor to help decrease the tumor volume that would have resulted in severe cosmetic and functional morbidity with resection. We favor giving radiation therapy after surgery, as a smaller volume of tumor cells exist, the margins of the non-radiated tumor can be better defined during surgery, and the postoperative wound healing is more predictable.

Chemotherapy

The role of chemotherapy for the treatment of tumors of the sinonasal tract is usually adjunctive to radiotherapy (radiosensitizer) or palliative, using its cytoreductive effect to relieve pain, obstruction, or to debulk a massive external lesion. It is increasingly being given concurrently with radiation and used in patients at high risk of recurrence, such as those with positive margins after resection, perineural spread, or extracapsular spread in regional metastases.

Surgical Therapy

Surgery

Surgical resection is usually performed with curative intent. Oftentimes, obtaining wide surgical margins may not be possible because of the proximity of critical structures. Postoperative radiation is then recommended to reduce the incidence of local recurrence. In some cases, palliative excision or debulking may be considered to alleviate intractable pain, or to relieve decompression of the optic nerve or orbit, or to drain obstructed paranasal sinuses.

Traditionally, the surgical resection is carried out in an en bloc fashion and usually via an open approach. The types of resection and surgical approaches used will depend on tumor size and its extension.

Tumors confined to the nasal cavity can be assessed via a variety of approaches including transanasal endoscopic, sublabial, lateral rhinotomy approaches or a combination of endoscopic and open techniques. Advanced tumors may require orbital exenteration, partial or total maxillectomy or anterior cranial base resection. Resection of the anterior skull base is considered the criterion standard for malignant tumors that are in contact with or transgress the anterior skull base. Select patients selected patients may be treated using endonasal-endoscopic approaches. Resections may be extended laterally to join a temporal craniotomy to include the pterygoid plates, the pterygopalatine fossa, and the floor of the middle cranial fossa en bloc.

Bony erosion of the orbital walls does not constitute an indication for orbital exenteration. In rare cases, the periorbita has been breached by tumor requiring an orbital exenteration. The prognosis in these cases is usually poor.

Absolute contraindications for surgery include those patients who are not medically fit due to medical or nutritional problems, presence of distant metastases, invasion of the prevertebral fascia, invasion of the cavernous sinus by a high-grade malignancy, involvement of the carotid artery in a high-risk patient (as determined by carotid flow studies), and bilateral invasion of the optic nerves or optic chiasm. Relative contraindications include invasion of the brain and intracranial involvement of neural structures by adenoid cystic carcinoma. These situations usually have a poor prognosis, but in selected patients a surgical resection may offer significant palliation or local control.

Recent advances in preoperative imaging, intraoperative navigation system, endoscopic instrumentation, and hemostatic materials have made endoscopic resection of nasal and paranasal sinus tumors a viable alternative to the traditional techniques. Its role in resecting small lesions confined to the nasal cavity is well established. With increasing experience, endoscopic endonasal approaches have expanded beyond the nasal cavity and paranasal sinuses to areas such as the infratemporal fossa and cranial cavity. Endoscopic techniques can be used alone or in combination with open approaches, according to the different degree of involvement of the anterior skull base.

The primary concern about using an entirely endoscopic approach to resect malignant sinonasal tumors is the adherence of oncological principles. Although the instrumentation may be different, the surgical strategy and goals are similar. En bloc excision of the entire tumor is not necessary; rather, the authors perform a sequential layered resection of the area of invasion. The cribriform plate and its attached dura from the posterior wall of the frontal sinus back to the planum sphenoidale and between the orbits can be resected sequentially with adequate margins. Frozen sections are used to confirm clear margins.

In order to reach the area of invasion, debulking the tumor first is frequently necessary. This does not violate normal tissue planes because the tumor is residing in an air-filled cavity. Currently, no evidence exists that debulking increases the risk of local recurrence. Examples of other neoplasms that are removed in a piecemeal without compromise of results include laser resection of pharyngeal and laryngeal squamous cell carcinomas and microscopically controlled excision of skin cancers in Moh’s technique.

Expansion of the indications to use an endonasal endoscopic approach for the resection of advanced sinonasal tumors that have transgressed the skull base followed the development of more effective means of reconstruction to seal off the intracranial cavity from the nasal cavity. The nasoseptal flap is the biggest advance in the reconstruction of the skull base in endoscopic sinus surgery.44 It drastically decreases the rate of cerebrospinal fluid leak. Other pedicled flaps that have been described for reconstruction include the tranasion pericranial flap, transpterygoid temporoparietal fascia flap, inferior turbinate flap, and palatal flap.

Advantages of the endoscopic approach include the avoidance of facial incisions, low morbidity and shorter length of hospital stay. Early oncologic outcomes are at least equivalent to those of open approaches, however, long long-term follow-up and larger cohorts of patients are needed before it gains universal acceptance.45,46

Contraindications to a completely endoscopic endonasal approach include invasion of the orbit, involvement of superficial tissues such as the anterior and lateral portion of the frontal sinus, anterior wall of the maxillary sinus and nasal bones, and invasion of the skin.

Reconstruction

Wide resection of tumors of the nasal cavity and paranasal sinuses can result in facial disfigurement and speech and swallowing difficulties. The main goals of postsurgical rehabilitation of these massive multilayered defects are primary wound healing, preservation or reconstruction of the facial contour, and restoration of oronasal separation, thus facilitating speech and swallowing and separation of the nasal cavity from the cranial cavity. Functional considerations take precedence over aesthetics.

Reconstruction options range from simple closure to the use of free tissue grafts (fat, cadaveric acellular dermis, fascia) to the use of vascularized flaps such as pedicled regional flaps (eg, pectoralis major, latissimus dorsi, trapezius) or free microvascular flaps (eg, radial forearm, anterolateral thigh), as seen in the images below. Flaps are recommended to replace resected facial skin, to provide support for the orbit or brain, or to isolate the cranial cavity from the nasal cavity. A dental obturator or prosthesis is commonly used for oronasal separation, although in patients undergoing a free flap the fistula is usually corrected as part of the reconstruction.

In lateral rhinotomy, a straight incision is made...

In lateral rhinotomy, a straight incision is made at the naso-maxillary junction followed by a curvilinear incision around the nasal ala.

In lateral rhinotomy, a straight incision is made...

In lateral rhinotomy, a straight incision is made at the naso-maxillary junction followed by a curvilinear incision around the nasal ala.


A Weber-Ferguson incision is usually indicated fo...

A Weber-Ferguson incision is usually indicated for a total maxillectomy.

A Weber-Ferguson incision is usually indicated fo...

A Weber-Ferguson incision is usually indicated for a total maxillectomy.


A cranial base resection with a view of the anter...

A cranial base resection with a view of the anterior skull base and nasal cavity from the top.

A cranial base resection with a view of the anter...

A cranial base resection with a view of the anterior skull base and nasal cavity from the top.


Follow-up

Routine, long-term follow-up is necessary for proper oncological surveillance. Examination of the treated site can help to identify recurrence or even a new primary tumor. Rigid or flexible endoscopy can help to facilitate this evaluation in a postoperative patient. Abnormal findings or new symptoms that are suspicious for recurrence warrant further radiological evaluation (CT scan, MRI, or both).

Complications

Surgical

The extensive nature of surgical resection can cause a variety of complications including bleeding, cerebrospinal fluid leak, infection (including intracranial abscess and meningitis), and blindness. 

The proximity of the eye can also lead to potentially severe ophthalmic complications. Sacrifice of the nasolacrimal duct during a maxillectomy and subsequent stenosis of the lacrimal sac opening may lead to epiphora. Performing a dacryocystorhinostomy during resection can prevent this complication. Limitation of extraocular eye movement may occur after trauma to the muscle, its motor innervation, or upon entrapment in craniofacial osteotomies. This latter complication should be managed by urgent surgical release. Limitation of extraocular muscle movement due to edema or neuromuscular contusion is managed expectantly. Alternating eye patching may alleviate diplopia.

The optic nerve may be compressed during the mobilization of the specimen or during craniofacial resection. High-dose steroids and emergent surgical decompression are recommended. Enophthalmos or hypophthalmos may develop because of the loss of the inferior orbital and/or medial support and can be prevented with appropriate reconstructive techniques.

Radiation therapy

Traditionally, external beam radiation fields include the anterior (eyelids, conjunctiva, lacrimal gland and apparatus, cornea, lens, and the rest of the anterior chamber) and posterior orbital segments. This can result in orbital complications in close to 100% of patients. Anterior segment irradiation may lead to dry eye, severe keratitis, panophthalmitis, and blindness within a year. Enucleation may be necessary for uncontrolled panophthalmitis or a painful eye. If the anterior segment is spared, a delayed loss of vision may still develop in 3-5 years due to postradiation retinopathy or optic neuropathy.

The incidence of these complications is related to total dose and fractionation and increase with the use of concomitant chemoradiation. They are rare below 3500 cGy, 50-65% with 6000-7000 cGy, and above 85% with 8000 cGy. Other common side effects from radiation therapy include xerostomia, mucositis, trismus, and osteonecrosis.

Over the past 2 decades, 3D conformal radiation therapy and, more recently, intensity modulated radiation therapy (IMRT) have replaced conventional external beam. These techniques minimize the dose delivered to vitals structures close to the tumor. As a result, side effects from high-dose radiation have decreased, and the patients’ quality of life has improved. This is achieved without compromising the clinical outcome for the patients.47

With IMRT, the incidence of optic nerve and other ocular complications have greatly decreased.15,48,49,50 Claus et al compared the complication rates of external beam radiation with 3D-conformation and IMRT in 47 patients who underwent postoperative radiation following resection of adenocarcinoma of the ethmoid sinuses. Radiation-induced severe dry eye syndrome, characterized by chronic conjunctivitis and keratitis, and accompanied by a significant decrease of the vision was observed in 7 cases, all of whom were treated with conventional radiation techniques. Enucleation of the eye was necessary in one patient to control the symptoms. Another 2 patients had optic neuropathy. No neuropathy was found in the group treated with IMRT.15
 
Chen et al reported a longitudinal study of 127 patients treated with RT from 1960-2005 at UCSF. The incidence of grade 3 and 4 late ocular toxicity among patients treated with conventional RT, 3D CRT, and IMRT was 20%, 9%, and 0%, respectively.48 In another series by Hoppe et al, none of the patients who underwent IMRT developed Grade 3–4 late ocular complications.49 As the experience with IMRT increases, the late complication rates are anticipated to also continue to decrease.

The North American Skull Base Society is currently investigating the role of high-dose IMRT and concomitant cisplatin chemotherapy with or without surgery for advanced paranasal cancers. The protocol is under development with the goal to determine the feasibility of nonsurgical therapy for these tumors in a multi-institution setting.47

Wound complications

Wound complications include bleeding, infection (skin, meningitis, or intracranial abscess), and loss of reconstructive flaps or skin grafts. Crusting in the nasal cavity after surgery or irradiation is a common problem and may lead to infection. Frequent irrigation with normal saline solution can soften the crust and maintain nasal hygiene. Meningitis or intracranial abscess is more likely in the presence of a CSF fistula, which can occur after destruction of the skull base and disruption of the dura mater. Treatment involves intravenous antibiotics, drainage of intracranial abscess, and repair of the fistula with dural graft or vascularized flap, if available. Osteoradionecrosis of the maxilla or mandible can occur in up to 10% of patients with poor dentition and recently extracted dentition. Antibiotics and local debridement of the necrotic bone will be needed.

More on Malignant Tumors of the Nasal Cavity

Overview: Malignant Tumors of the Nasal Cavity
Workup: Malignant Tumors of the Nasal Cavity
Treatment: Malignant Tumors of the Nasal Cavity
Follow-up: Malignant Tumors of the Nasal Cavity
Multimedia: Malignant Tumors of the Nasal Cavity
References

References

  1. Zimmer LA, Carrau RL. Neoplasms of the nose and paranasal sinuses. In: Bailey BJ, Johnson JT, Newland SD, eds. Head & Neck Surgery - Otolaryngology. 4th. Lippincott, Williams & Wilkins; 2006.

  2. Caplan LS, Hall I, Levine RS, Zhu K. Preventable risk factors for nasal cancer. Ann Epidemiol. 2000;10:186-91.

  3. Weymuller EA, Gal TJ. Neoplasms of the nasal cavity. In: Cummings CW, Flint PW, Harker LA et al. eds. Otolaryngology - Head and Neck surgery. 4th. Mosby; 2005.

  4. d'Errico A, Pasian S, Baratti A, et al. A case-controlled study on occupational risk factors for sino-nasal cancer. Occup Environ Med. 2009;66:448-55.

  5. Benninger MS. The impact of cigarette smoking and environmental tobacco smoke on nasal and sinus disease: a review of the literature. Am J Rhinol. Nov-Dec 1999;13(6):435-8. [Medline].

  6. Jackson RT, Fitz-Hugh GS, Constable WC. Malignant neoplasms of the nasal cavities and paranasal sinuses: (a retrospective study). Laryngoscope. May 1977;87(5 Pt 1):726-36. [Medline].

  7. Snyderman CH, Carrau RL, deVries EJ. Johnson JT, Derkay CS, Mandell-Brown MK, Newman RK eds. Carotid artery resection: update on preoperative evaluation. 6. Mosby; 1993:341-4.

  8. Mansell NJ, Bates GJ. The inverted Schneiderian papilloma: a review and literature report of 43 new cases. Rhinology. Sep 2000;38(3):97-101. [Medline].

  9. Schlosser RJ, Mason JC, Gross CW. Aggressive endoscopic resection of inverted papilloma: an update. Otolaryngol Head Neck Surg. Jul 2001;125(1):49-53. [Medline].

  10. Kraft M, Simmen D, Kaufmann T, Holzmann D. Long-term results of endonasal sinus surgery in sinonasal papillomas. Laryngoscope. Sep 2003;113(9):1541-7. [Medline].

  11. Hanna EYN, Westfall C. Cancer of the nasal cavity, paranasal sinuses and orbit. In: Myers EN, Suen JY, Myers JN, Hanna EYN, eds. Cancer of the head and neck. 4th. Saunders; 2003.

  12. Barnes L. Surgical pathology of the head and neck. 2nd. Marcel Dekker; 2001.

  13. Kida A, Endo S, Iida H, et al. Clinical assessment of squamous cell carcinoma of the nasal cavity proper. Auris Nasus Larynx. 1995;22(3):172-7. [Medline].

  14. Heffner DK, Hyams VJ, Hauck KW, Lingeman C. Low-grade adenocarcinoma of the nasal cavity and paranasal sinuses. Cancer. Jul 15 1982;50(2):312-22. [Medline].

  15. Claus F, Boterberg T, Ost P, et al. Postoperative radiotherapy for adenocarcinoma of the ethmoid sinuses: treatment results for 47 patients. Int J Radiat Oncol Biol Phys. Nov 15 2002;54(4):1089-94. [Medline].

  16. Knegt PP, Ah-See KW, vd Velden LA, Kerrebijn J. Adenocarcinoma of the ethmoidal sinus complex: surgical debulking and topical fluorouracil may be the optimal treatment. Arch Otolaryngol Head Neck Surg. Feb 2001;127(2):141-6. [Medline].

  17. Almeyda R, Capper J. Is surgical debridement and topical 5 fluorouracil the optimum treatment for woodworkers' adenocarcinoma of the ethmoid sinuses? A case-controlled study of a 20-year experience. Clin Otolaryngol. Oct 2008;33(5):435-41. [Medline].

  18. Rhee CS, Won TB, Lee CH, et al. Adenoid cystic carcinoma of the sinonasal tract: treatment results. Laryngoscope. Jun 2006;116(6):982-6. [Medline].

  19. Lupinetti AD, Roberts DB, Williams MD, et al. Sinonasal adenoid cystic carcinoma: the M. D. Anderson Cancer Center experience. Cancer. Dec 15 2007;110(12):2726-31. [Medline].

  20. Szanto PA, Luna MA, Tortoledo ME, White RA. Histologic grading of adenoid cystic carcinoma of the salivary glands. Cancer. Sep 15 1984;54(6):1062-9. [Medline].

  21. Spiro RH. Distant metastasis in adenoid cystic carcinoma of salivary origin. Am J Surg. Nov 1997;174(5):495-8. [Medline].

  22. Frierson HF Jr, Mills SE, Fechner RE, Taxy JB, Levine PA. Sinonasal undifferentiated carcinoma. An aggressive neoplasm derived from schneiderian epithelium and distinct from olfactory neuroblastoma. Am J Surg Pathol. Nov 1986;10(11):771-9. [Medline].

  23. Enepekides DJ. Sinonasal undifferentiated carcinoma: an update. Curr Opin Otolaryngol Head Neck Surg. Aug 2005;13(4):222-5. [Medline].

  24. Cerilli LA, Holst VA, Brandwein MS, Stoler MH, Mills SE. Sinonasal undifferentiated carcinoma: immunohistochemical profile and lack of EBV association. Am J Surg Pathol. Feb 2001;25(2):156-63. [Medline].

  25. Mendenhall WM, Mendenhall CM, Riggs CE Jr, Villaret DB, Mendenhall NP. Sinonasal undifferentiated carcinoma. Am J Clin Oncol. Feb 2006;29(1):27-31. [Medline].

  26. Hyams VJ. Olfactory neuroblastoma (case 6). In: Batsakis JG, Hyams VJ, Morales AR, eds. Specifial tumors of the head and neck. Chicago: American Society of Clinical Pathologist Press; 1992:24-29.

  27. Dulguerov P, Calcaterra T. Esthesioneuroblastoma: the UCLA experience 1970-1990. Laryngoscope. Aug 1992;102(8):843-9. [Medline].

  28. Folbe A, Herzallah I, Duvvuri U, et al. Endoscopic endonasal resection of esthesioneuroblastoma: a multicenter study. Am J Rhinol Allergy. Jan-Feb 2009;23(1):91-4. [Medline].

  29. Devaiah AK, Andreoli MT. Treatment of esthesioneuroblastoma: a 16-year meta-analysis of 361 patients. Laryngoscope. Jul 2009;119(7):1412-6. [Medline].

  30. Dulguerov P, Allal AS, Calcaterra TC. Esthesioneuroblastoma: a meta-analysis and review. Lancet Oncol. Nov 2001;2(11):683-90. [Medline].

  31. Loy AH, Reibel JF, Read PW, et al. Esthesioneuroblastoma: continued follow-up of a single institution's experience. Arch Otolaryngol Head Neck Surg. Feb 2006;132(2):134-8. [Medline].

  32. Dauer EH, Lewis JE, Rohlinger AL, Weaver AL, Olsen KD. Sinonasal melanoma: a clinicopathologic review of 61 cases. Otolaryngol Head Neck Surg. Mar 2008;138(3):347-52. [Medline].

  33. Mendenhall WM, Amdur RJ, Hinerman RW, Werning JW, Villaret DB, Mendenhall NP. Head and neck mucosal melanoma. Am J Clin Oncol. Dec 2005;28(6):626-30. [Medline].

  34. Lund VJ, Howard DJ, Harding L, Wei WI. Management options and survival in malignant melanoma of the sinonasal mucosa. Laryngoscope. Feb 1999;109(2 Pt 1):208-11. [Medline].

  35. Wagner M, Morris CG, Werning JW, Mendenhall WM. Mucosal melanoma of the head and neck. Am J Clin Oncol. Feb 2008;31(1):43-8. [Medline].

  36. Hillstrom RP, Zarbo RJ, Jacobs JR. Nerve sheath tumors of the paranasal sinuses: electron microscopy and histopathologic diagnosis. Otolaryngol Head Neck Surg. Mar 1990;102(3):257-63. [Medline].

  37. Hicks J, Flaitz C. Rhabdomyosarcoma of the head and neck in children. Oral Oncol. Jul 2002;38(5):450-9. [Medline].

  38. Hawkins WG, Hoos A, Antonescu CR, et al. Clinicopathologic analysis of patients with adult rhabdomyosarcoma. Cancer. Feb 15 2001;91(4):794-803. [Medline].

  39. Fyrmpas G, Wurm J, Athanassiadou F, et al. Management of paediatric sinonasal rhabdomyosarcoma. J Laryngol Otol. Sep 2009;123(9):990-6. [Medline].

  40. Raney RB, Meza J, Anderson JR, et al. Treatment of children and adolescents with localized parameningeal sarcoma: experience of the Intergroup Rhabdomyosarcoma Study Group protocols IRS-II through -IV, 1978-1997. Med Pediatr Oncol. Jan 2002;38(1):22-32. [Medline].

  41. Herve S, Abd Alsamad I, Beautru R, et al. Management of sinonasal hemangiopericytomas. Rhinology. Dec 1999;37(4):153-8. [Medline].

  42. Vidal RW, Devaney K, Ferlito A, Rinaldo A, Carbone A. Sinonasal malignant lymphomas: a distinct clinicopathological category. Ann Otol Rhinol Laryngol. Apr 1999;108(4):411-9. [Medline].

  43. Nasal cavity and paranasal sinues. In: Greene FL, Page DL, Fleming ID, et al. eds. AJCC Cancer Staging Manual. 6. New York: Springer - Verlga; 2002:59-67.

  44. Hadad G, Bassagasteguy L, Carrau RL, et al. A novel reconstructive technique after endoscopic expanded endonasal approaches: vascular pedicle nasoseptal flap. Laryngoscope. Oct 2006;116(10):1882-6. [Medline].

  45. Nicolai P, Battaglia P, Bignami M, et al. Endoscopic surgery for malignant tumors of the sinonasal tract and adjacent skull base: a 10-year experience. Am J Rhinol. May-Jun 2008;22(3):308-16. [Medline].

  46. Lund V, Howard DJ, Wei WI. Endoscopic resection of malignant tumors of the nose and sinuses. Am J Rhinol. Jan-Feb 2007;21(1):89-94. [Medline].

  47. Lee NY, Le QT. New developments in radiation therapy for head and neck cancer: intensity-modulated radiation therapy and hypoxia targeting. Semin Oncol. Jun 2008;35(3):236-50. [Medline].

  48. Chen AM, Daly ME, Bucci MK, et al. Carcinomas of the paranasal sinuses and nasal cavity treated with radiotherapy at a single institution over five decades: are we making improvement?. Int J Radiat Oncol Biol Phys. Sep 1 2007;69(1):141-7. [Medline].

  49. Hoppe BS, Stegman LD, Zelefsky MJ, et al. Treatment of nasal cavity and paranasal sinus cancer with modern radiotherapy techniques in the postoperative setting--the MSKCC experience. Int J Radiat Oncol Biol Phys. Mar 1 2007;67(3):691-702. [Medline].

  50. Daly ME, Chen AM, Bucci MK, et al. Intensity-modulated radiation therapy for malignancies of the nasal cavity and paranasal sinuses. Int J Radiat Oncol Biol Phys. Jan 1 2007;67(1):151-7. [Medline].

  51. Patel SG, Singh B, Polluri A, et al. Craniofacial surgery for malignant skull base tumors: report of an international collaborative study. Cancer. Sep 15 2003;98(6):1179-87. [Medline].

  52. Suárez C, Ferlito A, Lund VJ, et al. Management of the orbit in malignant sinonasal tumors. Head Neck. Feb 2008;30(2):242-50. [Medline].

Further Reading

Keywords

malignant tumors of the nasal cavity, nasal cavity tumors, malignant tumors, nasal cavity, squamous cell carcinoma, SCCA, glandular tumor, adenocarcinoma, AC, adenoid cystic carcinoma

Contributor Information and Disclosures

Author

Ricardo L Carrau, MD, Professor, Department of Otolaryngology-Head and Neck Surgery, Department of Neurological Surgery, Department of Oral and Maxillofacial Surgery, University of Pittsburgh School of Medicine; Professor of Oral and Maxillofacial Surgery, University of Pittsburgh School of Dental Medicine
Ricardo L Carrau, MD is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery, American College of Surgeons, American Medical Association, American Rhinologic Society, American Society for Head and Neck Surgery, North American Skull Base Society, Pennsylvania Medical Society, and Triological Society
Disclosure: Storz Endoscopy Inc Honoraria Speaking and teaching; Stryker Navigation Honoraria Speaking and teaching

Coauthor(s)

Yew Kwang Ong, MBBCh, Fellow in Craniofacial/Skull Base Surgery, Department of Otolaryngology, University of Pittsburgh Medical Center
Disclosure: Nothing to disclose.

C Arturo Solares, MD, Assistant Professor of Otolaryngology, Co-Director, MCG Skull Base Institute, Department of Otolaryngology-Head and Neck Surgery, Medical College of Georgia
C Arturo Solares, MD is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery, American College of Surgeons, American Rhinologic Society, and Triological Society
Disclosure: Nothing to disclose.

Medical Editor

William M Lydiatt, MD, Professor and Division Director, Head and Neck Surgical Oncology, Department of Otolaryngology-Head and Neck Surgery, University of Nebraska Medical Center
William M Lydiatt, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Otolaryngology-Head and Neck Surgery, American College of Surgeons, American Head and Neck Society, and Nebraska Medical Association
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Nader Sadeghi, MD, FRCS(C), Associate Professor of Surgery, Director of Head and Neck Surgery, Division of Otolaryngology, George Washington University
Nader Sadeghi, MD, FRCS(C) is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery, American Head and Neck Society, Federation of Medical Specialists in Quebec, and Royal College of Physicians and Surgeons of Canada
Disclosure: Nothing to disclose.

CME Editor

Christopher L Slack, MD, Otolaryngology-Facial Plastic Surgery, Private Practice, Associated Coastal ENT; Medical Director, Treasure Coast Sleep Disorders
Christopher L Slack, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, and American Medical Association
Disclosure: Nothing to disclose.

Chief Editor

Arlen D Meyers, MD, MBA, Professor, Department of Otolaryngology-Head and Neck Surgery, University of Colorado School of Medicine
Arlen D Meyers, MD, MBA is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, and American Head and Neck Society
Disclosure: Covidien Corp Consulting fee Consulting; US Tobacco Corporation unstricted gift unknown; Axis Three Corporation Ownership interest Consulting; Omni Biosciences Ownership interest Consulting; Sentegra Ownership interest Board membership; Syndicom Ownership interest Consulting; Oxlo  Consulting; Medvoy Ownership interest Management position

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.